Article
Preprint Research on Pfizer COVID-19 Vaccine Shows Greater Efficacy Two Weeks Post Administration
Author(s):
New data from an unreviewed, preprint research article indicate first-dose immunization efficacy of the Pfizer-BioNTech coronavirus 2019 vaccine improves by 51% 13-24 days post administration.
New data from an unreviewed, preprint research article indicates first-dose immunization efficacy from Pfizer-BioNTech coronavirus 2019 (COVID-19) vaccine BNT162b2 is improved 51% after 13-24 days among Israel residents given the vaccine. The retrospective cohort assessment, pending review and publication, is among the first real-world indications of first-dose efficacy of the currently authorized mRNA vaccines for the pandemic.
Israel is currently the most vaccinated country against COVID-19, per capita, worldwide. According to Our World in Data, more than one-third of the total population has received at least 1 COVID-19 vaccine dose as of Thursday—or, nearly 3 million people. Off the strength of phase 3 results for BNT162b2—which was used to support its approved Emergency Use Authorization (EUA) under the FDA last month, and showed COVID-19 prevention efficacy of greater than 90% among adults after their second dose—the current understanding is that the Pfizer-BioNTech product is among the most promising prophylaxes for the pandemic virus.
That said, investigators wrote, real-life vaccine effectiveness evaluation during the rollout phase is “urgently needed, especially given the global disease surge.”
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease
